Tait T J, Le Gallez P, Astbury C, Bird H A
Clinical Pharmacology Unit (Rheumatism Research) Royal Bath Hospital, North Yorkshire, United Kingdom.
Clin Rheumatol. 1994 Mar;13(1):75-9. doi: 10.1007/BF02229869.
Low-dose methotrexate has gained widespread acceptance as a second-line agent in rheumatoid arthritis (RA). The Leeds Human Model Screening System (LHMSS) is a validated screening mechanism allowing the rapid evaluation of compounds for their potential as anti-rheumatic agents, the results of which have been confirmed in longer term studies. We have evaluated methotrexate in patients with RA using the LHMSS at a maintenance dose of 10mg/week. Significant change occurred in four out of eleven variables over a 24-week period (p < 0.01). This degree of change is greater than that seen with nonsteroidal anti-inflammatory agents but less than with other recognised second-line agents such as D-penicillamine, suggesting that methotrexate may have less potential as a second-line agent than D-penicillamine.
低剂量甲氨蝶呤作为类风湿关节炎（RA）的二线药物已得到广泛认可。利兹人体模型筛选系统（LHMSS）是一种经过验证的筛选机制，可快速评估化合物作为抗风湿药物的潜力，其结果已在长期研究中得到证实。我们使用LHMSS对类风湿关节炎患者进行了甲氨蝶呤评估，维持剂量为每周10毫克。在24周期间，11个变量中有4个出现了显著变化（p < 0.01）。这种变化程度大于非甾体抗炎药，但小于其他公认的二线药物，如青霉胺，这表明甲氨蝶呤作为二线药物的潜力可能比青霉胺小。
